Active Ingredient: GADOLINIUM
Gadolinium-Based Contrast Agents (GCAs) used in MRI imaging do not commonly affect the rate-corrected QT interval in routine, acute clinical settings. Although pre-market safety data for gadobenate (MultiHance®) previously reported QTc prolongations of >30ms in up to 55% of patients, a real-world prospective study of 24 adults receiving various formulations (MultiHance, ProHance, OptiMARK, Omniscan) showed no statistically significant changes. Mean QTc-Bazett shifted insignificantly from 395 ms to 396 ms (p = 0.549$, and mean QTc-Fridericia changed from 384 ms to 381 ms (p = 0.603). No patient experienced a QTc increase >30ms. While routine acute use appears electrophysiologically safe, manufacturing labels still warn of rare post-market cardiac arrests and arrhythmias, and a role for concomitant QTc-prolonging drugs or genetic predispositions cannot be entirely ruled out.
https://doi.org/10.7759/cureus.9668, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021357s014,021358s013lbl.pdf